Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-25. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
== Resources == Casss Times Archived 2006-09-28 at the Wayback Machine, Spring 2005 Casss Times Archived 2006-09-28 at the Wayback Machine, Autumn 2005 California Death Index Robert G Brownlee Marine project Archived 2014-04-15 at the Wayback Machine Article in The Scientist, June 1990 Applied Biosystems Timeline
==== Philanthropy ==== As chairman emeritus of Ferring, Paulsen is a founding sponsor of The Peptide Therapeutics Foundation. He has contributed to the opening of several fertility clinics throughout Russia to help solve its demographics problem. He has donated approximately $40 million to the Museum Kunst der Westküste (Museum of West Coast Art). He has also substantially contributed to the Salk Institute in San Diego, California, Bhutan's Royal Textile Academy and the South Georgia Heritage Trust in Scotland.
===== β-Ketoglutaric acid and TET-2 ===== β-Ketoglutaric acid has been detected in the saliva of individuals chewing betel quid, a complex mixture derived from betel nuts mixed with various other materials. Chronic chewing betel quid is associated with the development of certain cancers, particularly those in the oral cavity. The study showed that β-ketoglutaric acid bound to the cancer-promoting protein TET-2 thereby inhibiting α-ketoglutarate's binding to this protein. Since α-ketoglutarate's binding of TET-2 is thought to be required for it to activate TET-2, the study suggested that β-ketoglutaric acid may not fulfill the requirements for TET-2 to be activatable and therefore may prove able to block α-ketoglutarate's cancer-promoting as well as inflammation-promoting and other actions that involve its activation of TET-2.
1993/3156) European Communities (Definition of Treaties) (European Investment Fund) Order 1993 (S.I. 1993/3157) Drug Trafficking Offences Act 1986 (Designated Countries and Territories) (Amendment) (No. 2) Order 1993 (S.I. 1993/3158) Environment and Safety Information (Northern Ireland) Order 1993 (S.I. 1993/3159) Roads (Northern Ireland) Order 1993 (S.I. 1993/3160) Merchant Shipping (Fire Protection) (Non-United Kingdom) (Non-SOLAS Ships) (Amendment) Rules 1993 (S.I. 1993/3161) Merchant Shipping (Fire Appliances) (Amendment) Regulations 1993 (S.I. 1993/3162) Merchant Shipping (Fire Protection) (Amendment) Regulations 1993 (S.I. 1993/3163) Merchant Shipping (Fire Protection) (Ships Built Before 25 May 1980) (Amendment) Regulations 1993 (S.I. 1993/3164) Water and Sewerage Services (Amendment) (Northern Ireland) Order 1993 (S.I. 1993/3165) Ministerial and other Salaries Order 1993 (S.I. 1993/3166) Redundancy Payments (National Health Service) (Modification) Order 1993 (S.I. 1993/3167) Finance Act 1985 (Interest on Tax) (Prescribed Rate) (No. 2) Order 1993 (S.I. 1993/3168) Local Government Act 1992 (Commencement No. 3) Order 1993 (S.I. 1993/3169) Town and Country Planning (Fees for Applications and Deemed Applications) (Amendment) Regulations 1993 (S.I. 1993/3170) Taxes (Interest Rate) (Amendment No. 4) Regulations 1993 (S.I. 1993/3171) National Health Service (General Dental Services) Amendment (No. 2) Regulations 1993 (S.I. 1993/3172) Commercial Agents (Council Directive) (Amendment) Regulations 1993 (S.I.
Sources: en.wikipedia.org
==== East Raleigh ==== East Raleigh is situated roughly from Capital Boulevard and the eastern side of I-440 beltline to the Neuse River, and extending as far south as Poole Road. Most of East Raleigh's development is along primary corridors such as U.S. 1 (Capital Boulevard), New Bern Avenue, Poole Road, Buffaloe Road, and New Hope Road. Neighborhoods in East Raleigh include Hedingham, Longview, Lockwood, Madonna Acres, New Hope, Thompson-Hunter and Wilder's Grove. The area is bordered to the east by the town of Knightdale.
== Prolactin == Agonists: Growth hormone Human placental lactogen Placental growth hormone (growth hormone variant) Prolactin S179D-hPRL Somatotropin Antagonists: Δ1–9-G129R-hPRL Δ1–14-G129R-hPRL G120K-hGH G129R-hPRL Prolactin modulators: Prolactin inhibitors: D2 receptor agonists (e.g., bromocriptine, cabergoline); Prolactin releasers: D2 receptor antagonists (e.g., domperidone, metoclopramide, risperidone) Estrogens (e.g., estradiol) Progestogens (e.g., progesterone)
== History == In 1942, James Hamilton observed that prepubertal castration prevents the later development of male pattern baldness in mature men. In 1974, Julianne Imperato-McGinley of Cornell Medical College in New York attended a conference on birth defects. She reported on a group of intersex children in the Caribbean who appeared sexually ambiguous at birth, and were initially raised as girls, but then grew external male genitalia and other masculine characteristic after onset of puberty. These children, despite being raised as girls until puberty, were generally heterosexual and were termed "Guevedoces" by their local community, which means "penis at twelve" in Spanish. Her research group found these children shared a genetic mutation, causing deficiency of the 5α-reductase enzyme and male hormone dihydrotestosterone (DHT), which was found to have been the etiology behind abnormalities in male sexual development. Upon maturation, these individuals were observed to have smaller prostates which were underdeveloped, and were also observed to lack incidence of male pattern baldness. In 1975, copies of Imperato-McGinley's presentation were seen by P. Roy Vagelos, who was then serving as Merck's basic research chief. He was intrigued by the notion that decreased levels of DHT led to the development of smaller prostates. Dr. Vagelos then sought to create a drug that could mimic the condition found in these children to treat older men who had benign prostatic hyperplasia. Finasteride was developed by Merck under the code name MK-906.
=== Heart disease === Tricuspid regurgitation is usually secondary to right ventricular dilation which may be due to left ventricular failure (the most common cause), right ventricular infarction, inferior myocardial infarction, or cor pulmonale Other causes of tricuspid regurgitation include carcinoid syndrome and myxomatous degeneration.
== Business segments == Bio-Rad's life science products primarily include instruments, software, consumables, reagents, and content for the areas of cell biology, gene expression, protein purification, protein quantitation, drug discovery and manufacture, food safety, and science education. These products are based on technologies to separate, purify, identify, analyze, and amplify biological materials such as antibodies, proteins, nucleic acids, cells, and bacteria. Bio-Rad's diagnostic products and systems use a range of technologies and provide clinical information in the blood transfusion, diabetes monitoring, autoimmune, and infectious disease testing markets. These products are used to support the diagnosis, monitoring, and treatment of diseases and other medical conditions.
Sources: en.wikipedia.org
=== Implantable devices === The development of implantable devices like pacemakers and spinal cord stimulators also began in the mid-20th century. Devices to manage pain received FDA (USA) approval in the late 1960s. In 1967, Dr. Norm Shealy from Western Reserve Medical School presented "the first dorsal column stimulator for pain control". It was developed based on the Gate Theory of Wall and Melzack, which stated that pain transmissions from tiny nerve fibers would be blocked if competing transmissions were made along larger sensory nerve fibers. In 1973, Prof Hosbuchi reported relieving the denervation facial pain of anesthesia dolorosa via lasting electrical stimulation of the somatosensory thalamus, which marked the beginning of the age of deep-brain stimulation. In 1987, the team of neurosurgeons/neurologists Professor Benabid and Professor Pollak and their colleagues (Grenoble, France) published results on this topic about thalamic Deep Brain Stimulation. Deep brain stimulation began to be used to treat motor symptoms of movement disorders such as Parkinson's disease. In 1989, the International Neuromodulation Society (INS) was founded in Paris after the first International Congress on Epidural Spinal Cord Stimulation in Groningen, the Netherlands, by a select group of physicians: Dr. Augustinsson, a Swedish neurosurgeon; Dr. Galley, a French cardiologist; Dr. Illis, a British neurologist; Dr. Kranick, a German neurosurgeon: Dr. Meglio, an Italian Neurosurgeon; Dr. Sier, a Dutch vascular surgeon and Dr. Staal, a Dutch neurosurgeon.
==== The Iberian Peninsula ==== The Normans began appearing in the military confrontations between Christians and Muslims in the Iberian Peninsula since the early eleventh century. The first Norman who appears in the narrative sources was Roger I of Tosny who according to Ademar of Chabannes and the later Chronicle of St Pierre le Vif went to aid the Barcelonese in a series of raids against the Andalusi Muslims c. 1018. Later in the eleventh century, other Norman adventurers such as Robert Crispin and Walter Giffard participated in the probably papal organised siege of Barbastro of 1064. Even after the Norman conquest of England in 1066, the Normans continued to participate in ventures in the peninsula. After the Frankish conquest of the Holy Land during the First Crusade, the Normans began to be encouraged to participate in ventures of conquest in the northeast of the peninsula. The most significant example of this was the incursion of Rotrou II of Perche and Robert Burdet in the 1120s in the Ebro frontier. By 1129 Robert Burdet had been granted a semi-independent principality in the city of Tarragona by the then Archbishop of this see, Oleguer Bonestruga. Several others of Rotrou's Norman followers were rewarded with lands in the Ebro valley by King Alfonso I of Aragon for their services. With the rising popularity of the sea route to the Holy Land, Norman and Anglo-Norman crusaders also started to be encouraged locally by Iberian prelates to participate in the Portuguese incursions into the western areas of the Peninsula.
== External links == Overview of all the structural information available in the PDB for UniProt: Q04760 (Human Lactoylglutathione lyase) at the PDBe-KB. Overview of all the structural information available in the PDB for UniProt: Q9CPU0 (Mouse Lactoylglutathione lyase) at the PDBe-KB.
In the 1970s, antineoplastic (chemotherapy) drugs were identified as hazardous, and the American Society of Health-System Pharmacists (ASHP) has since then introduced the concept of hazardous drugs after publishing a recommendation in 1983 regarding handling hazardous drugs. The adaptation of federal regulations came when the U.S. Occupational Safety and Health Administration (OSHA) first released its guidelines in 1986 and then updated them in 1996, 1999, and, most recently, 2006. The National Institute for Occupational Safety and Health (NIOSH) has been conducting an assessment in the workplace since then regarding these drugs. Occupational exposure to antineoplastic drugs has been linked to multiple health effects, including infertility and possible carcinogenic effects. A few cases have been reported by the NIOSH alert report, such as one in which a female pharmacist was diagnosed with papillary transitional cell carcinoma. Twelve years before the pharmacist was diagnosed with the condition, she had worked for 20 months in a hospital where she was responsible for preparing multiple antineoplastic drugs. The pharmacist did not have any other risk factor for cancer, and therefore, her cancer was attributed to the exposure to the antineoplastic drugs, although a cause-and-effect relationship has not been established in the literature. Another case happened when a malfunction in biosafety cabinetry is believed to have exposed nursing personnel to antineoplastic drugs. Investigations revealed evidence of genotoxic biomarkers two and nine months after that exposure.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.